Journal Article

Effect of losartan on TGF‐<i>β</i>1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria

Enric Esmatjes, Lilliam Flores, Pablo Iñigo, Sergio Lario, Luis M. Ruilope and Josep M. Campistol

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 16, issue suppl_1, pages 90-93
Published in print May 2001 | ISSN: 0931-0509
Published online May 2001 | e-ISSN: 1460-2385 | DOI:
Effect of losartan on TGF‐β1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria

Show Summary Details


Background. The aim of the present study was to determine the effect of losartan on transforming growth factor‐β1 (TGF‐β1) plasma levels and urinary albumin excretion (UAE) in patients with type 2 diabetes mellitus, mild hypertension and microalbuminuria.

Methods. Fourteen patients (eight males, aged 55±6 years) with type 2 diabetes mellitus, mild arterial hypertension and microalbuminuria, participating in an open, uncontrolled, pilot study were included. Patients were treated for 8 weeks with losartan. TGF‐β1 plasma levels, UAE and 24‐h blood pressure monitoring were determined at baseline and at 4 and 8 weeks.

Results. At 4 and 8 weeks of treatment, a reduction was observed in TGF‐β1 plasma levels (5.5±4.5 vs 2.0±0.6 and 2.6±1.0 ng/ml, P<0.005), UAE (96±65 vs 59±59 and 64±47 μg/min, P<0.01), 24‐h systolic blood pressure (136±9 vs 129±9 and 130±10 mmHg, P<0.01) and 24‐h diastolic blood pressure (77±9 vs 74±8 and 74±7 mmHg, P<0.03). Stratifying the patients by baseline TGF‐β1, seven had TGF‐β1 plasma values higher than normal controls. At 4 and 8 weeks, they showed a marked reduction in TGF‐β1 values (9.0±3.9 to 2.1±0.7 and 2.5±0.7 ng/ml, P<0.01) and UAE (106±83 to 49±42 and 38±26 μg/min, P<0.05), with good correlation between the percentage reduction of both parameters (r=0.83, P<0.01). The remaining seven patients, with normal baseline TGF‐β1 plasma levels, showed no change in TGF‐β1 plasma levels and UAE after treatment.

Conclusion. Treatment with losartan decreases TGF‐β1 plasma values and UAE in type 2 diabetes mellitus patients with high baseline TGF‐β1 levels, suggesting that TGF‐β1 may be a marker to detect patients who may particularly benefit from renin‐angiotensin system blockade.

Keywords: hypertension; losartan; microalbuminuria; transforming growth factor‐β1; type 2 diabetes

Journal Article.  0 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.